clinical trial · NCT06903611
Phase III Study of Topical Fibrinogen-Depleted Human Platelet Lysate Compared to Placebo for Moderate to Severe Dry Eye
Dry Eye DiseaseDry EyeDry Eyes ChronicDry Eye SyndromesCAM-101Vehicle Control
brief summary
Prospective, multicenter, randomized, vehicle-controlled, double-masked, study of CAM-101 topical ophthalmic solution compared to vehicle control followed by crossover to long-term follow-up open-label treatment with CAM-101 for one year.
started
Sep 30, 2025
primary completion
Nov 1, 2026
completion
Dec 1, 2027
last updated
May 18, 2025
detailed description
The primary objective of this study is to evaluate the safety and efficacy of CAM-101 (FD hPL 30% v/v) topical ophthalmic solution after 9 weeks of treatment for moderate to severe dry eye disease and to evaluate the safety of CAM-101 (FD hPL 30%v/v) after 52-weeks of consecutive use
official title
CAMOMILE-3: Phase III Randomized, Double-Masked, Safety and Efficacy Study of Topical Fibrinogen-Depleted Human Platelet Lysate Compared to Vehicle Control for the Treatment of Moderate to Severe Dry Eye
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol